Download PDF
Horm Metab Res 2007; 39(10): 743-751
DOI: 10.1055/s-2007-985847
Review

© Georg Thieme Verlag KG Stuttgart · New York

Chromium in Metabolic and Cardiovascular Disease

M. Hummel 1 , E. Standl 1 , O. Schnell 1
  • 1Diabetes Research Institute & Academical Hospital Munich-Schwabing, Munich, Germany
Further Information

Publication History

received 21. 11. 2006

accepted 19. 03. 2007

Publication Date:
22 October 2007 (online)

Also available at
    Permissions and Reprints

Abstract

Chromium is an essential mineral that appears to have a beneficial role in the regulation of insulin action, metabolic syndrome, and cardiovascular disease. There is growing evidence that chromium may facilitate insulin signaling and chromium supplementation therefore may improve systemic insulin sensitivity. Tissue chromium levels of subjects with diabetes are lower than those of normal control subjects, and a correlation exists between low circulating levels of chromium and the incidence of type 2 diabetes. Controversy still exists as to the need for chromium supplementation. However, supplementation with chromium picolinate, a stable and highly bioavailable form of chromium, has been shown to reduce insulin resistance and to help reduce the risk of cardiovascular disease and type 2 diabetes. Since chromium supplementation is a safe treatment, further research is necessary to resolve the confounding data. The existing data suggest to concentrate future studies on certain forms as chromium picolinate and doses as at least 200 mcg per day.

Key words

chromium - chromium picolinate - diabetes - cardiovascular risk - insulin - metabolic syndrome

References

  • 1 Food and Nutrition Board .Recommended dietary allowances. 10th ed. Washington, DC: National Academy Press 2000
  • 2 Anderson RA. Chromium, glucose intolerance and diabetes.  J Am Coll Nutr. 1998;  17 548-555
    CrossrefPubMedGoogle Scholar
  • 3 Jeejeebhoy KN, Chu RC, Marliss EB, Greenberg GR, Bruce-Robertson A. Chromium deficiency, glucose intolerance, and neuropathy reversed by chromium supplementation in a patient receiving long-term total parenteral nutrition.  Am J Clin Nutr. 1977;  30 531-538
    PubMedGoogle Scholar
  • 4 Freund H, Atamian S, Fischer JE. Chromium deficiency during total parenteral nutrition.  JAMA. 1979;  241 496-498
    CrossrefPubMedGoogle Scholar
  • 5 Brown RO, Forloines-Lynn S, Cross RE, Heizer WD. Chromium defi-ciency after long-term total parenteral nutrition.  Dig Dis Sci. 1986;  31 661-664
    CrossrefPubMedGoogle Scholar
  • 6 Anderson RA. Chromium and parenteral nutrition.  Nutrition. 1995;  11 83-86
    PubMedGoogle Scholar
  • 7 Nielsen F. Controversial chromium: does the superstar mineral of the mountebanks receive appropriate attention from clinicians and nutritionists?.  Nutr Today. 1996;  31 226-233
    PubMedGoogle Scholar
  • 8 Anderson R, Cheng N, Bryden N. et al . Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.  Diabetes. 1997;  46 1786-1791
    CrossrefPubMedGoogle Scholar
  • 9 Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium.  J Am Coll Nutr. 1997;  16 404-410
    PubMedGoogle Scholar
  • 10 Vincent JB. Elucidating a biological role for chromium at a molecular level.  Acc Chem Res. 2000;  33 503-510
    CrossrefPubMedGoogle Scholar
  • 11 Anderson RA, Polansky MM, Bryden NA. Stability and absorption of chromium and adsorption of chromium histidinate complexes by humans.  Biol Trace Elem Res. 2004;  101 211-218
    CrossrefPubMedGoogle Scholar
  • 12 Anderson RA, Bryden NA, Evock-Clover M, Steele NC. Beneficial effects of chromium on glucose and lipid variables in control and somatotropin-treated pigs are associated with increased tissiue chromium and altered tissiue copper, iron, and zinc.  J Anim Sci. 1997;  75 657-661
    PubMedGoogle Scholar
  • 13 Anderson RA, Bryden NA, Polansky MM, Gautschl K. Dieatary chromium effects on tissue chromium concentrations and chromium absorption in rats.  J Trace Elem Exp Med. 1996;  9 12-25
    PubMedGoogle Scholar
  • 14 Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willett WC, Hu FB. Lower toenail chromium in men with diabetes and cardiovas-cular disease compared with healthy men.  Diabetes Care. 2004;  27 2211-2216
    PubMedGoogle Scholar
  • 15 Doisy RJ, Streeten DHP, Freiberg JM, Schneider AJ. Chromium metabolism in man and biochemical effects. In: Prasad AS, Oberleas D (eds). Trace Elements in Human Health and Disease: Essential and Toxic Elements. Vol. 2 New York: Marcel Dekker 1976
    Google Scholar
  • 16 Bunker VW, Lawson MS, Delves HT, Clayton BE. The uptake and excretion of chromium in the elderly.  Am J Clin Nutr. 1984;  39 797-802
    PubMedGoogle Scholar
  • 17 Saad MJA. Molecular mechanisms of insulin resistance.  Braz J Med Biol Res. 1994;  27 941-957
    PubMedGoogle Scholar
  • 18 Kahn CR. Current concepts of the molecular mechanism of insulin action.  Ann Rev Med. 1985;  36 429-451
    CrossrefPubMedGoogle Scholar
  • 19 Roth RA, Lui F, Chin JE. Biochemical mechanisms of insulin resistance.  Horm Res. 1994;  41 ((Suppl 2)) 51-55
    PubMedGoogle Scholar
  • 20 Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor kinase activity.  Biochemistry. 1997;  36 4382-4385
    CrossrefPubMedGoogle Scholar
  • 21 Vincent JB. The quest for the molecular mechanism of chromium action and its relationship to diabetes.  Nutr Rev. 2000;  58
    PubMedGoogle Scholar
  • 22 Yamamoto A, Wada O, Ono T. Isolation of a biologically active low-molecular-mass chromium compound from rabbit liver.  Eur J Biochem. 1987;  165 627-631
    CrossrefPubMedGoogle Scholar
  • 23 Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity.  Biochemistry. 1997;  36 4382-4385
    CrossrefPubMedGoogle Scholar
  • 24 Rabinowitz MB, Gonick HC, Levine SR, Davidson MB. Clinical trial of chromium and yeast supplements on carbohydrate and lipid metabolism in diabetic men.  Biol Trace Elem Res. 1983;  5 449-466
    PubMedGoogle Scholar
  • 25 Uusitupa MIJ, Kumpulainen JT, Voutilainen E, Hersio K, Sarlund H, Pyorala KP, Koivistoinen P, Lehto JT. Effect of inorganic chromium supplementation on glucose tolerance, insulin response and serum lipids in noninsulin-dependent diabetics.  Am J Clin Nutr. 1983;  38 404-410
    PubMedGoogle Scholar
  • 26 Mossop RT. Effects of chromium (III) on fasting glucose, cholesterol and cholesterol HDL levels in diabetics.  Cent Afr J Med. 1983;  29 80-82
    PubMedGoogle Scholar
  • 27 Nath R, Minocha J, Lyall V, Sunder S, Kumar V, Kapoor S, Dhar KL. Assessment of chromium metabolism in maturity onset and juvenile diabetes using chromium-51 and therapeutic response of chromium administration on plasma lipids, glucose tolerance and insulin levels. In Shapcott D, Hubert J (eds) Chromium in Nutrition and Metabolism. Amsterdam: Elsevier/North Holland 1979: 213-222
    Google Scholar
  • 28 Wang ZQ, Zhang XH, Russell JC, Hulver M, Cefalu WT. Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats.  J Nutr. 2006;  136 415-420
    PubMedGoogle Scholar
  • 29 Chen G, Liu P, Pattar GR, Tackett L, Bhonagiri P, Strawbridge AB, Elmendorf JS. Chromium activates glucose transporter 4 trafficking and enhances insulin-stimulated glucose transport in 3T3-L1 adipocytes via a cholesterol-dependent mechanism.  Mol Endocrinol. 2006;  20 857-870
    PubMedGoogle Scholar
  • 30 Pattar GR, Tackett L, Liu P, Elmendorf JS. Chromium picolinate positively influences the glucose transporter system via affecting cholesterol homeostasis in adipocytes cultured under hyperglycemic diabetic conditions.  Mutat Res. 2006;  610 93-100
    PubMedGoogle Scholar
  • 31 Glinsmann W, Mertz W. Effect of trivalent chromium on glucose tolerance.  Metabolism. 1966;  15 510-520
    CrossrefPubMedGoogle Scholar
  • 32 Sherman L, Glennon JA, Brech WJ, Klomberg GH, Gordon ES. Failure of trivalent chromium to improve hyperaglycemia in diabetes mellitus.  Metabolism. 1968;  17 439-442
    CrossrefPubMedGoogle Scholar
  • 33 Offenbacher KG, Pi-Sunyer X. Beneficial effect of chromium-rich yeast on glucose tolerance and blood lipids in elderly subjects.  Diabetes. 1980;  29 919-925
    CrossrefPubMedGoogle Scholar
  • 34 Elias AN, Grossman MK, Valenta LJ. Use of the artificial beta cell (ABC) in the assessment of peripheral insulin sensitivity; effect of chro-mium supplementation in diabetic patients.  Gen Pharmacol. 1984;  15 535-539
    PubMedGoogle Scholar
  • 35 Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans.  Int J Biosoc Med Res. 1989;  11 163-180
    PubMedGoogle Scholar
  • 36 Roeback  Jr  JR, Mae K, Chambless LE, Fletcher RH. Effects of chro-mium supplementation on serum high-density lipoprotein cholesterol levels in men taking beta-blockers.  Ann Intern Med. 1991;  115 917-924
    PubMedGoogle Scholar
  • 37 Abraham AS, Brooks BA, Eylath U. The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes.  Metabolism. 1992;  41 768-771
    CrossrefPubMedGoogle Scholar
  • 38 Lee NA, Reasner CA. Beneficial effect of chromium supplementa-tion on serum triglyceride levels in NIDDM.  Diabetes Care. 1994;  17 1449-1452
    CrossrefPubMedGoogle Scholar
  • 39 Ravina A, Slezak L, Rubal A, Mirsky N. Clinical use of the trace element chromium (III) in the treatment of diabetes mellitus.  J Trace Elem Exp Med. 1995;  8 183-190
    PubMedGoogle Scholar
  • 40 Jovanovic-Peterson L, Gutierry M, Peterson CM. Chromium supplementation for gestational diabetic women (GDM) improves glucose tolerance and decreases hyperinsulinemia.  Diabetes. 1996;  43 337
    PubMedGoogle Scholar
  • 41 Thomas VLK, Gropper SS. Effect of chromium nicotinic acid supplementation on selected cardiovascular disease risk factors.  Biol Trace Elem Res. 1997;  55 297-305
    PubMedGoogle Scholar
  • 42 Anderson RA, Cheng N, Bryden NA, Polansky MM, Chi J, Feng J. Beneficial effects of chromium for people with diabetes.  Diabetes. 1997;  46 1786-1791
    CrossrefPubMedGoogle Scholar
  • 43 Ravina A, Slezak L, Mirsky N, Bryden NA, Anderson RA. Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium.  Diabet Med. 1999;  16 164-167
    CrossrefPubMedGoogle Scholar
  • 44 Cheng N, Zhu X, Shi H, Wu W, Chi J, Cheng J, Anderson R. Follow-up survey of people in China with type 2 diabetes mellitus con-suming supplemental chromium.  J Trace Elem Exp Med. 1999;  12 55-60
    CrossrefPubMedGoogle Scholar
  • 45 Cefalu WT, Bell-Farrow AD, Stegner J, Wang ZQ, King T, Morgan T, Terry JG. Effect of chromium picolinate on insulin sensitivity in vivo.  J Trace Elem Exp Med. 1999;  12 71-83
    CrossrefPubMedGoogle Scholar
  • 46 Trow LG, Lewis J, Greenwood RH, Sampson MJ, Self KA, Crews HM, Fairweather-Tait SJ. Lack of effect of dietary chromium supplementation on glucose tolerance, plasma insulin and lipoprotein levels in patients with type 2 diabetes.  Int J Vitam Nutr Res. 2000;  70 14-18
    CrossrefPubMedGoogle Scholar
  • 47 Morris BW, Kouta S, Robinson R, MacNeil S, Heller S. Chromium supplementation improves insulin resistance in patients with type 2 diabetes mellitus.  Diabet Med. 2000;  17 684-685
    CrossrefPubMedGoogle Scholar
  • 48 Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Showdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus.  J Nutr Biochem. 2002;  13 690-697
    PubMedGoogle Scholar
  • 49 Gunton JE, Cheung NW, Hitchman R, Hams G, O’Sullivan C, Foster-Powell K, MacElduff A. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance.  Diabetes Care. 2005;  28 712-713
    CrossrefPubMedGoogle Scholar
  • 50 Kleefstra N, Houweling ST, Jansman FG, Groenier KH, Gans RO, Meyboom-de Jong B, Bakker SJ, Bilo HJ. Chromium treatment has no Effect in patients with poorly controlled, insulin-treated type 2 diabetes in an obese western population. A randomized, double-blind, placebo-controlled trial.  Diabetes Care. 2006;  29 521-525
    CrossrefPubMedGoogle Scholar
  • 51 Vrtovec M, Vrtovec B, Briski A, Kocijancic A, Anderson RA, Radovancevic B. Chromium supplementation shortens QTc interval duration in patients with type 2 diabetes mellitus.  Am Heart J. 2005;  149 632-635
    CrossrefPubMedGoogle Scholar
  • 52 Martin J, Wang ZQ, Zhang XH. et al . Chormium picolinate supplementation attenuates body weight gain and increases insulin sensiti-vity in subjects with type 2 diabetes.  Diabetes Care. 2006;  29 1826-1832
    CrossrefPubMedGoogle Scholar
  • 53 Bahijri SM, Mira SA, Mufti AM, Ajabnoor MA. The effects of inorganic chromium and brewer's yeast supplementation on glucose tolerance, serum lipids and drug dosage in individuals with type 2 diabetes.  Saudi Med J. 2000;  21 831-837
    PubMedGoogle Scholar
  • 54 Bahijri SM, Mufti AM. Beneficial effects of chromium in people with type 2 diabetes, and urinary chromium response to glucose load as a possible indicator of status.  Biol Trace Elem Res. 2002;  85 97-109
    CrossrefPubMedGoogle Scholar
  • 55 Komorowski J, Juturu V. Chromium supplementation does not improve glucose tolerance, insulin sensitivity, or lipid profile: a randomized, placebo-controlled, double-blind trial of supplementation in subjects with impaired glucose tolerance. Response to Gunton et al.  Diabetes Care. 2005;  28 1841-1842
    PubMedGoogle Scholar
  • 56 Althuis MD, Jordan NE, Ludington EA, Wittes JT. Glucose and insulin responses to dietary chromium supplements: a meta-analysis.  Am J Clin Nutr. 2002;  76 148-155
    PubMedGoogle Scholar
  • 57 Pittler MH, Stevinson C, Ernst E. Chromium picolinate for reducing body weight: meta-analysis of randomized trials.  Int J Obes Relat Metab Disord. 2003;  27 522-529
    CrossrefPubMedGoogle Scholar
  • 58 Uusitupa MI, Mykkanen L, Siitonen O, Laakso M, Sarlund H, Kolehmainen P, Rasanen T, Kumpulainen J, Pyorala K. Chromium supplementation in impaired glucose tolerance of elderly: effects on blood glucose, plasma insulin, C-peptide and lipid levels.  Br J Nutr. 1992;  68 209-216
    PubMedGoogle Scholar
  • 59 Volpe SL, Huang HW, Larpadisorn K, Lesser II. Effect of chromium supplementation and exercise on body composition, resting meta-bolic rate and selected biochemical parameters in moderately obese women following an exercise program.  J Am Coll Nutr. 2001;  20 293-306
    PubMedGoogle Scholar
  • 60 Cefalu WT, Hu FB. Role of chromium in human health and in diabetes.  Diabetes Care. 2004;  27 2741-2751
    CrossrefPubMedGoogle Scholar
  • 61 Anderson RA. Chromium, glucose tolerance, diabetes and lipid metabolism.  J Adv Med. 1995;  8 37-49
    PubMedGoogle Scholar
  • 62 Kaats GR, Keith SC, Wise JA, Pullin D, Squires WG. Effects of baseline total cholesterol levels on diet and exercise interventions.  JANA. 1999;  2 42-49
    PubMedGoogle Scholar
  • 63 Boyd SG, Boone BE, Smith AR, Conners J, Dohm GL. Combined dietary chromium picolinate supplementation and an exercise program leads to a reduction of serum cholesterol and insulin in college-aged subjects.  J Nutr Biochem. 1998;  9 471-475
    PubMedGoogle Scholar
  • 64 Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects.  West J Med. 1990;  152 41-45
    PubMedGoogle Scholar
  • 65 Guallar E, Jimenez FJ, Veer P van’t, Bode P, Riemersma RA, Gomez-Aracena J, Kark JD, Arab L, Kok FJ, Martin-Moreno JM. EURAMIC-Heavy Metals and Myocardial Infarction Study Group . Low toenail chromium concentration and increased risk of nonfatal myocardial infarction.  Am J Epidemiol. 2005;  162 157-164
    CrossrefPubMedGoogle Scholar
  • 66 Jain SK, Patel P, Rogier K, Jain SK. Trivalent chromium inhibits protein glycosylation and lipid peroxidation in high glucose-treated erythrocytes.  Antioxid Redox Signal. 2006;  8 238-241
    CrossrefPubMedGoogle Scholar
  • 67 American Diabetes Association . Standards of medical care in diabetes (Position Statement).  Diabetes Care. 2006;  29 ((Suppl 1)) 14
    PubMedGoogle Scholar
  • 68 Vincent JB. The Biochemistry of Chromium.  J Nutr. 2000;  130 715-718
    PubMedGoogle Scholar
  • 69 http://www.cfsan.fda.gov/~dms/qhccr.html

Correspondence

Dr. M. Hummel

Diabetes Research Institute & Academical Hospital Munich-Schwabing

Koelner Platz 1

80804 Munich

Germany

Phone: +49/89/306 834 30

Fax: +49/89/308 17 33

Email: Michael.Hummel@lrz.uni-muenchen.de

      >